Amrutanjan Health Care FY26 PAT Rises to ₹57.92 Cr; Declares ₹2.90 Dividend
Amrutanjan Health Care reported FY26 PAT of ₹57.92 crore, up from ₹50.83 crore in FY25. Revenue from operations reached ₹502.55 crore. A final dividend of ₹2.90 per share is recommended. The 89th AGM is on September 23, 2026. The dividend record date is September 11, 2026.
The announcement includes key financial results, dividend declaration, and details about the upcoming AGM, which are material information for investors. The forward-looking statements about new product launches and manufacturing plant commencement also have a significant impact.
The company reported increased profits, revenue, and recommended a dividend, indicating positive financial performance. The announcement also includes forward-looking statements about new product launches and capacity expansion.
Amrutanjan Health Care Limited has announced its Business Responsibility and Sustainability Report for the Financial Year 2025-26, which forms part of the Annual Report. The company reported a Profit After Tax (PAT) of ₹57.92 crore for FY26, an increase from ₹50.83 crore in FY25. The Board of Directors has recommended a final dividend of ₹2.90 per equity share for the financial year ended March 31, 2026. The 89th Annual General Meeting (AGM) is scheduled to be held on Wednesday, September 23, 2026, at 10:30 AM IST, through Video Conference (VC)/Other Audio-Visual Means (OAVM). The record date for the payment of dividend has been fixed as Friday, September 11, 2026. The company's revenue from operations for FY26 stood at ₹502.55 crore, with a Profit Before Tax (PBT) of ₹77.89 crore. The company also highlighted its expansion into personal care, ortho pain, and nasal care categories in FY2026 and plans to relaunch its congestion-relief brand, Relief, in FY2027. The new sanitary pad manufacturing plant is expected to commence operations in May 2027, enhancing the profitability of the Comfy brand.
A plain-language summary of a public exchange filing by Amrutanjan Health Care Limited. Read the original for the full detail.